Moncharmont P, Janot C, Boudart D, Cotte C, Couroucé A M, Elghouzzi M H, Jullien A M, Lemaire J M, Maisonneuve P, Maniez-Montreuil M
CRTS de Lyon-Beynost.
Rev Fr Transfus Hemobiol. 1992 Jul;35(3):205-10. doi: 10.1016/s1140-4639(05)80124-8.
Hepatitis C virus (HCV) discovery and introduction of anti-HCV antibodies screening in blood transfusion imply the necessity of a good blood donations and blood donors policy. Detection of a seropositivity during the screening must be completed with a confirmatory test. The results are directly used to inform donors and define the blood products policy. Donors with positive results on confirmatory test are discarded and have physical and biological examinations in hepatology. Individuals with indeterminate or negative results must be retested for the HCV serology. Furthermore, because of a rapid improvement in the fields of technology, diagnosis and therapy of HCV, an adaptation of the policy is necessary.
